Lista de obras -

18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanoma

artículo científico publicado en 2017

A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy

artículo científico publicado en 2017

A gender factor in shaping T-cell immunity to melanoma

artículo científico publicado en 2015

ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance

artículo científico publicado en 2020

Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome

article

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

artículo científico publicado en 2014

Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations

scientific article published on 20 March 2020

Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma

artículo científico publicado en 2017

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

artículo científico publicado en 2016

BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma.

artículo científico publicado en 2016

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

article

Bim and PD-1 identify effector CD8 T cells responsive to anti-PD-1 therapy in metastatic melanoma patients.

artículo científico publicado en 2015

Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy

artículo científico publicado en 2019

CD5+ B-cell lymphoproliferative disorders: Beyond chronic lymphocytic leukemia and mantle cell lymphoma

artículo científico publicado en 2010

CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity.

artículo científico publicado en 2010

CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.

artículo científico publicado en 2018

Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up

artículo científico publicado en 2013

Cardiac Metastasis in Renal Cell Carcinoma without Vena Cava or Atrial Involvement: an Unusual Presentation of Metastatic Disease

artículo científico publicado en 2013

Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine

artículo científico publicado en 2019

Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients

artículo científico publicado en 2020

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy

artículo científico publicado en 2018

Contraction of T cell richness in lung cancer brain metastases.

artículo científico publicado en 2018

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

scientific article published on 01 December 2018

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

artículo científico publicado en 2017

Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients

artículo científico publicado en 2016

Effect of β-adrenergic blockers and other antihypertensive drugs on the risk of melanoma recurrence and death--I

artículo científico publicado en 2014

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.

artículo científico publicado en 2017

Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients

artículo científico publicado en 2013

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

artículo científico publicado en 2016

Fluctuation of systemic immunity in melanoma and implications for timing of therapy ⬇️

artículo científico publicado el 1 de enero de 2012

Immune Checkpoint Inhibitor Toxicities

scientific article published on 01 July 2019

Immune checkpoint molecules soluble program death ligand 1 and galectin-9 are increased in pregnancy

artículo científico publicado en 2017

Immunomodulatory antibody therapy of cancer: the closer, the better

artículo científico publicado en 2014

Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma

artículo científico publicado en 2014

In Reply - Immune Checkpoint Inhibitor-Induced Type 1 Diabetes: An Underestimated Risk

artículo científico publicado en 2020

Increasing incidence of melanoma among middle-aged adults: an epidemiologic study in Olmsted County, Minnesota

artículo científico publicado en 2014

Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.

artículo científico publicado en 2014

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

artículo científico publicado en 2020

Low hypoxia inducible factor-1α (HIF-1α) expression in testicular germ cell tumors - a major reason for enhanced chemosensitivity?

artículo científico publicado en 2017

Melanoma brain metastases and vemurafenib: need for further investigation

artículo científico publicado en 2012

NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma.

artículo científico publicado en 2017

NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy

artículo científico publicado en 2021

NUT midline carcinoma: an aggressive intrathoracic neoplasm

artículo científico publicado en 2013

Normal ageing is associated with an increase in Th2 cells, MCP-1 (CCL1) and RANTES (CCL5), with differences in sCD40L and PDGF-AA between sexes.

artículo científico publicado en 2012

Paradox-driven adventures in the development of cancer immunology and immunotherapy

scientific article published on 10 July 2019

Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC).

artículo científico publicado en 2014

Peptide vaccine with glucopyranosyl lipid A-stable oil-in-water emulsion for patients with resected melanoma

scientific article published on 05 August 2020

Personalized therapy for metastatic melanoma: could timing be everything?

artículo científico publicado en 2012

Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.

artículo científico publicado en 2014

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma

artículo científico publicado en 2016

Prospective Immunophenotyping of CD8+ T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT

artículo científico publicado en 2018

Rare presentations of primary melanoma and special populations: a systematic review

artículo científico publicado en 2014

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

artículo científico publicado en 2013

Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?

artículo científico publicado en 2019

Sex-Based Differences in Melanoma Survival in a Contemporary Patient Cohort

scientific article published on 27 February 2020

Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992-2011.

artículo científico publicado en 2017

T cell Bim levels reflect responses to anti-PD-1 cancer therapy.

artículo científico publicado en 2016

Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer

artículo científico publicado en 2016

The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma

artículo científico publicado en 2015

The dynamic human immune response to cancer: it might just be rocket science

article by Shernan G Holtan et al published 1 September 2011 in Immunotherapy

The use of pembrolizumab for the treatment of metastatic uveal melanoma

artículo científico publicado en 2016

Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles

artículo científico publicado en 2020

VTE and mortality associated with erythropoiesis-stimulating agents in cancer-associated anemia

artículo científico publicado en 2008

Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma

artículo científico publicado en 2017

Lista de obras de

18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanoma

A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy

A gender factor in shaping T-cell immunity to melanoma

ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance

Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations

Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma.

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Bim and PD-1 identify effector CD8 T cells responsive to anti-PD-1 therapy in metastatic melanoma patients.

Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy

CD5+ B-cell lymphoproliferative disorders: Beyond chronic lymphocytic leukemia and mantle cell lymphoma

CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity.

CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.

Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up

Cardiac Metastasis in Renal Cell Carcinoma without Vena Cava or Atrial Involvement: an Unusual Presentation of Metastatic Disease

Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine

Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy

Contraction of T cell richness in lung cancer brain metastases.

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients

Effect of β-adrenergic blockers and other antihypertensive drugs on the risk of melanoma recurrence and death--I

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.

Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

Fluctuation of systemic immunity in melanoma and implications for timing of therapy ⬇️

Immune Checkpoint Inhibitor Toxicities

Immune checkpoint molecules soluble program death ligand 1 and galectin-9 are increased in pregnancy

Immunomodulatory antibody therapy of cancer: the closer, the better

Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma

In Reply - Immune Checkpoint Inhibitor-Induced Type 1 Diabetes: An Underestimated Risk

Increasing incidence of melanoma among middle-aged adults: an epidemiologic study in Olmsted County, Minnesota

Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

Low hypoxia inducible factor-1α (HIF-1α) expression in testicular germ cell tumors - a major reason for enhanced chemosensitivity?

Melanoma brain metastases and vemurafenib: need for further investigation

NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma.

NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy

NUT midline carcinoma: an aggressive intrathoracic neoplasm

Normal ageing is associated with an increase in Th2 cells, MCP-1 (CCL1) and RANTES (CCL5), with differences in sCD40L and PDGF-AA between sexes.

Paradox-driven adventures in the development of cancer immunology and immunotherapy

Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC).

Peptide vaccine with glucopyranosyl lipid A-stable oil-in-water emulsion for patients with resected melanoma

Personalized therapy for metastatic melanoma: could timing be everything?

Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma

Prospective Immunophenotyping of CD8+ T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT

Rare presentations of primary melanoma and special populations: a systematic review

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?

Sex-Based Differences in Melanoma Survival in a Contemporary Patient Cohort

Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992-2011.

T cell Bim levels reflect responses to anti-PD-1 cancer therapy.

Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer

The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma

The dynamic human immune response to cancer: it might just be rocket science

The use of pembrolizumab for the treatment of metastatic uveal melanoma

Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles

VTE and mortality associated with erythropoiesis-stimulating agents in cancer-associated anemia

Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma